Compounds > oleracein e

Page last updated: 2024-11-13

oleracein e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oleracein E: antioxidant from Portulaca oleracea; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Portulaca	genus	A plant genus of the family PORTULACACEAE.[MeSH]	Portulacaceae	A plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. There are no true petals; each flower has two to six sepals. They produce betacyanin and betaxanthin pigments and lack anthocyanins.[MeSH]

Cross-References

ID Source	ID
PubMed CID	21574476
CHEMBL ID	2160181
MeSH ID	M0537672

Synonyms (16)

Synonym
inchi=1/c12h13no3/c14-10-5-7-3-4-13-9(1-2-12(13)16)8(7)6-11(10)15/h5-6,9,14-15h,1-4h2
ljidrfnrdlyhnc-uhfffaoysa-
CHEMBL2160181
(+/-)-trolline
8,9-dihydroxy-1,5,6,10b-tetrahydropyrrolo[2,1-a]isoquinolin-3(2h)-one
oleracein e
AKOS027330746
trolline
1021950-79-7
8,9-dihydroxy-2,5,6,10b-tetrahydro-1h-pyrrolo[2,1-a]isoquinolin-3-one
FS-8508
DTXSID30904168
()-trolline
CS-0062907
( inverted exclamation marka)-trolline
HY-113806

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay ID	Title	Year	Journal	Article
AID694395	Bactericidal activity against Escherichia coli CECT 405 at 0.2 mg/disk after 24 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694394	Bactericidal activity against Salmonella typhi CECT 409 at 0.2 mg/disk after 24 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694407	Fungicidal activity against Fusarium culmorum CCM 172 at 04 mg/disk after 48 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694391	Bactericidal activity against Bacillus cereus CECT 148 at 0.2 mg/disk after 24 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694405	Fungicidal activity against Aspergillus parasiticus CECT 2681 at 0.4 mg/disk after 48 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694392	Bactericidal activity against Staphylococcus aureus CECT 86 at 0.2 mg/disk after 24 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694397	Bactericidal activity against Erwinia carotovora CECT 225 at 0.2 mg/disk after 24 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694406	Fungicidal activity against Trichoderma viride CECT 2423 at 0.4 mg/disk after 48 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694408	Fungicidal activity against Phytophthora citrophthora CECT 2353 at 0.4 mg/disk after 48 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694393	Bactericidal activity against Enterococcus faecalis CECT 481 at 0.2 mg/disk after 24 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694409	Fungicidal activity against Geotrichum candidum CCM 245 at 0.4 mg/disk after 48 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
AID694396	Bactericidal activity against Escherichia coli CECT 100 at 0.2 mg/disk after 24 hrs by agar diffusion assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	7 (70.00)	24.3611
2020's	2 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	13.15 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	5.55 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (13.15)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.15	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.13	1	0	organonitrogen compound; organooxygen compound
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.15	1	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
galactose galactopyranose : The pyranose form of galactose.	7.13	1	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	7.15	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
veratric acid veratric acid: RN given refers to parent cpd; structure. 3,4-dimethoxybenzoic acid : A member of the class of benzoic acids that is benzoic acid substituted by methoxy groups at positions 2 and 3.	2.53	2	0	benzoic acids	allergen; plant metabolite
vanillic acid Vanillic Acid: A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).. vanillic acid : A monohydroxybenzoic acid that is 4-hydroxybenzoic acid substituted by a methoxy group at position 3.	2.53	2	0	methoxybenzoic acid; monohydroxybenzoic acid	plant metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.13	1	0	dialdehyde	biomarker
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2.6	1	0	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
benomyl [no description available]	2.07	1	0	aromatic amide; benzimidazole fungicide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	acaricide; anthelminthic drug; antifungal agrochemical; microtubule-destabilising agent; tubulin modulator
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.17	1	0	D-glucopyranose	epitope; mouse metabolite
vitexin [no description available]	2.17	1	0	C-glycosyl compound; trihydroxyflavone	antineoplastic agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite; platelet aggregation inhibitor
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.17	1	0	trihydroxyflavone	antineoplastic agent; metabolite
orientin orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer. orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.	2.17	1	0	3'-hydroxyflavonoid; C-glycosyl compound; tetrahydroxyflavone	antioxidant; metabolite
sodium nitrite Sodium Nitrite: Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines.. sodium nitrite : An inorganic sodium salt having nitrite as the counterion. Used as a food preservative and antidote to cyanide poisoning.	2.13	1	0	inorganic sodium salt; nitrite salt	antidote to cyanide poisoning; antihypertensive agent; antimicrobial food preservative; food antioxidant; poison
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.07	1	0
3-methyladenine N3-methyladenine: structure in first source	2.15	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Colitis Gravis [description not available]	0	2.6	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	0	7.6	1	0
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	0	2.6	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.59	2	0
Heart Disease, Ischemic [description not available]	0	2.25	1	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	0	2.25	1	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	0	2.13	1	0
Age-Related Memory Disorders [description not available]	0	2.13	1	0
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	0	2.13	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.15	1	0
Atherosclerotic Parkinsonism [description not available]	0	2.15	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2.15	1	0
Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)	0	2.15	1	0
Cirrhosis, Liver [description not available]	0	2.15	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	0	2.15	1	0